Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.

Pasha, Mohammed Khalid

Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. [electronic resource] - Drug metabolism letters Mar 2012 - 33-42 p. digital

Publication Type: Journal Article

1874-0758

10.2174/187231212800229336 doi


Administration, Oral
Animals
Antineoplastic Agents--administration & dosage
Biological Availability
Caco-2 Cells
Cyclin-Dependent Kinases--antagonists & inhibitors
Cytochrome P-450 Enzyme System--drug effects
Dogs
Female
Hepatocytes--enzymology
Heterocyclic Compounds, 4 or More Rings--administration & dosage
Humans
Inhibitory Concentration 50
Janus Kinase 2--antagonists & inhibitors
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Microsomes, Liver--metabolism
Rats
Rats, Wistar
Species Specificity
Tissue Distribution
fms-Like Tyrosine Kinase 3--antagonists & inhibitors